This inventor holds 1 USPTO granted patent. Top assignee: Boehringer Ingelheim Vetmedica Gmbh. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Norbet Poellinger: Innovator in Pharmaceutical Composition
Introduction
Norbet Poellinger is a notable inventor based in Müllheim, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of taste-masked compositions. His innovative work aims to improve the delivery of active ingredients in medications, making them more palatable for patients.
Latest Patents
Norbet Poellinger holds a patent for a "Taste masked pharmaceutical composition." This invention involves taste-masked multi-layered particles that include an inert core and one or more coating layers comprising a pharmaceutically active ingredient and a binder. The intermediate coating layer is free from low molecular weight water-soluble ionic compounds and includes a water-soluble pharmaceutical film-forming compound. The outer coating layer is designed to mask the taste of the active ingredient, which is often bitter or has a basic group. This innovative approach enhances the acceptability of medications for patients.
Career Highlights
Norbet Poellinger is associated with Boehringer Ingelheim Vetmedica GmbH, where he has been instrumental in advancing pharmaceutical technologies. His work focuses on creating formulations that improve patient compliance and overall treatment outcomes. With a patent portfolio that includes 1 patent, he continues to contribute to the field of veterinary medicine.
Collaborations
Norbet has collaborated with esteemed colleagues such as Martin Andreas Folger and Stefan Johannes Lehner. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas within the pharmaceutical industry.
Conclusion
Norbet Poellinger is a distinguished inventor whose work in taste-masked pharmaceutical compositions has the potential to transform patient experiences with medications. His contributions to the field are invaluable, and his ongoing efforts will likely lead to further advancements in pharmaceutical technology.